RT Journal Article
SR Electronic
T1 Increase in ventilatory ratio indicates progressive alveolar damage and suggests poor prognosis in severe COVID-19: A single-center retrospective observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.20.21260754
DO 10.1101/2021.07.20.21260754
A1 Kaku, Natsuko
A1 Nakagama, Yu
A1 Shirano, Michinori
A1 Shinomiya, Sari
A1 Shimazu, Kazuhiro
A1 Yamazaki, Katsuaki
A1 Maehata, Yoshito
A1 Morita, Ryo
A1 Nitahara, Yuko
A1 Yamamoto, Hiromasa
A1 Mizobata, Yasumitsu
A1 Kido, Yasutoshi
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.20.21260754.abstract
AB Background The symptoms of severe COVID-19 are complex and wide-ranging even in intensive care unit (ICU) patients, who may successfully discontinue respiratory support in a short period or conversely require prolonged respiratory support. Damage in the lungs of COVID-19 patients is characterized pathologically as diffuse alveolar damage, the degree of which correlates with the severity of the disease. We hypothesized that the ventilatory ratio (VR), a surrogate parameter for the dead space fraction, might stratify the severity of COVID-19 and predict the successful discontinuation of respiratory support.Methods Forty COVID-19 patients in our ICU were enrolled in this study. Respiratory variables were collected from 2 hours (day 0) after the initiation of respiratory support. We monitored the longitudinal values of VR and other respiratory parameters for 28 days. Patients successfully discontinued from respiratory support by day 28 of ICU stay were defined as the successfully discontinued group, while those who died or failed to discontinue were defined as the failed to discontinue group. VR and other respiratory parameters were compared between these groups.Results Except for advanced age, prolonged ventilation period, and higher mortality in the failed to discontinue group, there were no significant differences between the groups in terms of any other background or respiratory parameter at 2 hours (day 0) after initiation of respiratory support. Longitudinal VR monitoring revealed significantly higher VR values in the failed to discontinue group than the successfully discontinued group on day 4 of respiratory support. Upon predicting the failure to discontinue respiratory support, the area under the receiver operating characteristic curve of VR values on day 4 of respiratory support was 0.748. A threshold of 1.56 achieved the highest predictive performance with a sensitivity of 0.667 and a specificity of 0.762. This threshold enabled the prediction of the successfully discontinued outcome at 0.810 of the negative predictive value.Conclusions Elevated VR values on day 4 of respiratory support were predictive of successful discontinuation of respiratory support in patients with severe COVID-19. Longitudinal VR values after initiation of respiratory support can be used as a practical index to stratify severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Japan Agency for Medical Research and Development (AMED) under Grant number JP20wm0125003 (Yasutoshi Kido), JP20he1122001 (Yasutoshi Kido), JP20nk0101627 (Yasutoshi Kido), and JP20jk0110021 (Yu Nakagama). This work was also supported by JSPS KAKENHI Grans Number JP21441824 (Natsuko Kaku). We also receive the COVID-19 Private Fund (to the Shinya Yamanaka laboratory, CiRA, Kyoto University). We received support from Osaka City University's "Special Reserves" fund for COVID-19.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted under the approval of the Institutional Review Board of Osaka City University (#2020-003) and the Clinical Research Ethics Committee of the Osaka Municipal Hospital Organization (#2005020), Osaka, Japan.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current study are available in Microsoft Excel files titled 'Supplement Table 1－4'.ACE2angiotensin-converting enzyme 2ARDSacute respiratory distress syndromeAUCarea under ROC curveBMIbody mass indexCOVID-19Coronavirus disease 2019DADdiffuse alveolar damageCstatstatic lung complianceFiO2the fraction of inspired oxygenIBWideal body weightICUintensive care unitMERS-CoVmiddle east respiratory syndrome coronavirusMVminute ventilationPaCO2the partial pressure of carbon dioxidePaO2the partial pressure of oxygenPCRpolymerase chain reactionPEEPpositive end-expiratory pressurePplatplateau pressureP/FPaO2 / FiO2ROCreceiver operating characteristicSARS-CoVsevere acute respiratory syndrome coronavirusSARS-CoV-2severe acute respiratory syndrome coronavirus 2VD/VTdead space fractionVRventilatory ratioVTtidal volume